Bionano Genomics Q1 revenue up 4%, margin improves; to retire convertible debt

Bionano Genomics

13/05/2026 21:23

Overview

US genome analysis provider's Q1 2026 revenue rose 4% yr/yr to $6.7 mln

Gross margin for Q1 improved to 49% from 46% yr/yr

Company expects to retire secured convertible debt, strengthening financial position

Outlook

Company sees Q2 2026 revenue between $7.5 mln and $7.8 mln

Company expects full-year 2026 revenue between $30 mln and $33 mln

Result Drivers

CONSUMABLES GROWTH - Co reported 20% yr/yr increase in consumables revenue and 17% rise in flow cell sales, indicating higher platform utilization

BROADENING OGM ADOPTION - Co cited expanding use of optical genome mapping in clinical and research settings, supported by new CPT codes and positive publications

Company press release: ID:nGNX1qsHc2

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$6.70 mln
Q1 Gross Margin
49.00%
Q1 Adjusted Operating Expenses
$9.10 mln
Q1 Operating Expenses
$11.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Bionano Genomics Inc is $5.00, about 296.8% above its May 12 closing price of $1.26

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)